We found that ITPKB functions as an independent factor for poor prognoses and RUNX1 mutations in conjunction with ITPKB, CCDC12, and NBEAL2 have prognostic potential in AML. This evidence concerns the gene NBEAL2 and acute myeloid leukemia.